摘要
目的:探讨胰高血糖素样肽-1(glucagon-like peptide-1,GLP-1)类似物对2型糖尿病患者体质量及胰岛β细胞功能的影响。方法:新诊断的超重或肥胖2型糖尿病(DM)患者96例,随机分为GLP-1类似物治疗组(GLP-1组,n=40)及二甲双胍对照组(二甲双胍组,n=56),比较2组患者治疗前后腰围、体质量指数(Body Mass Index,BMI)、糖代谢指标(FPG,2 h PG,HbA1c)及胰岛β细胞功能的变化。结果:⑴治疗4月后与治疗前比较,两组FPG、2 h PG、HbA1C、FA均下降,GLP-1组2 h CP和腰围下降,差异均有统计学意义(P<0.05);⑵与二甲双胍组比较,GLP-1组HbA1c达标率更高(P<0.05),FCP和腰围改善明显,差异有统计学意义(P<0.05)。对患者按体质量指数基线分层后,中重度肥胖2型糖尿病患者(BMI>30 kg/m2)接受GLP-1治疗后体质量及腰围均下降;⑶多元逐步回归分析显示:FBG、BMI为FCP的重要影响因素,腰围、2 h PG为2 h CP的重要影响因素。结论:GLP-1类似物能有效改善2型糖尿病患者β细胞功能,降低空腹及餐后血糖,对中重度肥胖者兼有减重作用。
Objective To evaluate effects of glucagon-like peptide-1 receptor agonists on weight loss and β-cell function in overweight or obese patients with type 2 diabetes.Methods A total of 96 overweight or obese type 2 diabetic patients were randomly divided into GLP-1 group(n = 40) and metformin group(n = 56).The glycometabolism parameters including fasting plasma glucose(FPG),C-peptide(CP),oral glucose 2 h plasma glucose(2 h PG),2 h CP and hemoglobin(HbA1c),body mass index(BMI),waistline and β-cell function were measured.The changes of above indexes before and after therapy were compared between two groups.Results ⑴Compared with before therapy,the levels of FPG,2 h PG,HbA1c,FA were significantly decreased in both group after therapy for 4 months,the 2 h CP and waistline were significantly decreased in GLP-1 group as well(all P < 0.05);⑵Compared with metformin group,the rates of up to the standard was significant higher,the improvement of FCP and waistline was more obviously in GLP-1 group.In the different body weight subgroups,the body weight and waistline were significantly decreased in the moderate severe obesity patients with type 2 diabetes that BMI over 30 kg / m2(P < 0.05);⑶The multiple regression analysis demonstrated that FBG,BMI were the important factors of FCP,waistline and 2 h PG was the important factors of 2 h CP.Conclusion GLP-1 can effectively improve β-cell function,decrease the fasting and postprandial blood glucose of patients with type 2 diabetes,meanwhile,it is helpful to lose weight in moderate to severe obesity patients.
出处
《湖北医药学院学报》
CAS
2013年第3期213-216,共4页
Journal of Hubei University of Medicine
基金
十堰市科技局攻关项目基金资助(2006057D)
关键词
胰高血糖素样肽-1类似物
2型糖尿病
Β细胞功能
Glucagon-like peptide-1 receptor agonist
Type 2 diabetes mellitus
β-cell function
